Pair

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pair

Overview of Pair

Pair is a pharmacological treatment utilized in the management of specific health conditions. It belongs to a class of medications characterized by their targeted mechanism of action within the body. As a therapeutic option, it is primarily prescribed to address symptoms or underlying biological factors associated with diagnosed medical requirements.

Mechanism of Action

The primary function of Pair involves interacting with specific physiological pathways to modulate biological responses. By targeting these pathways, the medication helps to stabilize or improve the clinical presentation of the condition it is intended to treat. The precise interaction depends on the individual's health profile and the nature of the condition being managed.

Therapeutic Purpose

Pair is developed to assist patients in achieving better health outcomes through consistent management of their condition. It is often integrated into a broader care plan. The objective of using Pair is to provide a reliable method for symptom control and to support the long-term maintenance of physiological balance.

Clinical Applications

In clinical settings, Pair is recognized for its role in treating various stages of a specific condition. Healthcare providers evaluate the appropriateness of this medication based on diagnostic criteria and the unique needs of the patient. Its application is focused on providing a stable therapeutic effect over a designated period.

What side effects are possible with Pair?

Possible side effects and safety information

The official safety documentation for Pair (Ketorolac tromethamine) classifies adverse reactions across several major system-organ classes, with an emphasis on gastrointestinal, cardiovascular, and renal disorders. The incidence of these effects is formally categorized by regulatory authorities, with reactions such as headache, dizziness, nausea, and dyspepsia frequently classified as common in official documents, using the EMA/ICH frequency definitions.


Serious Adverse Reaction Tiers

Regulatory sources explicitly document the risk of serious, clinically significant events, which include gastrointestinal bleeding, ulceration, and perforation. Furthermore, the safety profile recognizes a potential association with serious cardiovascular thrombotic events, such as myocardial infarction and stroke. Rare but severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also listed.

Safety Patterns and Constraints

The risk of experiencing serious adverse reactions is formally recognized as being dose-related. To mitigate these serious, duration-dependent risks, regulatory labels mandate that the medicine must be used for a maximum total duration of five (5) days across all routes of administration. This short-term use constraint is a fundamental feature of the drug's safety authorization.

Specific safety considerations are documented for certain populations: older adults are officially noted to be at greater risk for developing serious gastrointestinal and renal adverse reactions. The medicine is also contraindicated in patients with advanced renal impairment, establishing a population-specific safety limitation.


These safety domains structure the official understanding of the drug's risk profile, linking the potent analgesic effect to a requirement for highly controlled, short-term use due to the documented potential for severe adverse events.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation describes the potential manifestations of an overdose of Pair (Ketorolac tromethamine). Common presentations include non-specific symptoms such as lethargy, drowsiness, nausea, vomiting, and specific gastrointestinal distress like epigastric pain or abdominal pain.

However, the regulatory profile highlights the risk of severe systemic outcomes. These documented, potentially life-threatening effects include acute renal failure, respiratory depression, and, rarely, coma. Other documented serious effects are gastrointestinal bleeding, peptic ulcers, and hypertension.

Management is limited as no specific antidote is known. Therefore, immediate attention requires the institution of symptomatic and supportive care. Regulatory labeling indicates that urgent medical help must be sought following any symptomatic overdose or the known ingestion of a large oral dose (cited as five to ten times the usual dose). In cases of recent ingestion (within four hours), specific supportive procedures such as the administration of activated charcoal and an osmotic cathartic are documented as potential interventions under clinical supervision.

Therapeutic Uses of Pair

What Pair Treats: Main Uses and Benefits

This medication is commonly used to help with the short-term relief of symptoms related to moderately severe acute pain. It is generally applied in clinical settings that involve acute or disruptive symptom patterns, where patients may require supportive assistance for high-intensity pain.


Key Therapeutic Applications

Pair is commonly used across conditions presenting with acute episodes, which include managing symptoms related to physical discomfort following surgical procedures, addressing pain from musculoskeletal trauma, and easing symptoms that become more disruptive during flare-ups like severe migraines. Its specialized ophthalmic form is also relevant for easing discomfort in the eye after surgery.

This medicine is considered relevant as a non-narcotic option that contributes to improved comfort during periods of heightened physical discomfort. It helps maintain a sense of stability when symptoms are more noticeable, assisting patients in coping more steadily with difficult episodes.

“It is commonly used to offer temporary assistance in symptom stabilization, particularly for pain that significantly interferes with daily functioning.”

Quick Fact: Symptomatic Assistance

Pair is applied in addressing symptom clusters where pain is compounded by localized inflammation and associated physical strain. It provides supportive relief when symptoms interfere with routine activities, especially for pain that requires management comparable to opioid-level analgesia.

Regulatory References

  1. NIH MedlinePlus overview of Ketorolac

Eligibility and Restrictions for Use

Who Can and Cannot Use Pair?

Eligibility for Pair (Ketorolac tromethamine) is strictly defined by regulatory authorities and centers on avoiding use in vulnerable populations and those with pre-existing conditions that increase risk. Pair is primarily intended for Adult Patients (generally 17 years and older) for short-term pain management.


Official Contraindications (Must Not Use)

Use is absolutely prohibited (contraindicated) in patients with specific conditions, including:

  • Gastrointestinal Risk: Active peptic ulcer disease, recent GI bleeding, or perforation.
  • Renal Impairment: Advanced kidney failure or risk of renal failure due to volume depletion.
  • Bleeding Risk: Confirmed cerebrovascular bleeding, hemorrhagic diathesis, or high bleeding risk.
  • Concomitant Use: Patients currently receiving aspirin or other NSAIDs.
  • Surgery: Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Special Population Restrictions

  • Age: The systemic product is not indicated for pediatric patients (under 17 years) as safety and efficacy have not been established. Older adults (65 years and older) require careful management.
  • Pregnancy & Lactation: Use is contraindicated during labor and delivery and in nursing mothers (breastfeeding). Avoidance is required in late pregnancy (from 30 weeks gestation).
  • Comorbidity: Patients with moderate renal impairment and those under 50 kg require conditional use with a reduced maximum daily limit.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information strictly outlines combinations that are contraindicated and those that require monitoring due to pharmacokinetic and pharmacodynamic interactions.

Interaction Classification Interacting Agents/Classes
Contraindicated Combinations Aspirin, other NSAIDs, Anticoagulants (e.g., Warfarin, Heparin), Probenecid, Pentoxifylline.
Exposure Modification Risk Lithium, Methotrexate, Digoxin.
Pharmacodynamic Risk ACE Inhibitors, ARBs, Diuretics, SSRIs, SNRIs, Oral Corticosteroids.

Exposure Modification and Clearance: Co-administration with Probenecid is contraindicated because it significantly increases Ketorolac plasma concentrations due to reduced clearance. Concomitant use with Lithium or Methotrexate is noted to increase the plasma levels and potential toxicity of these agents dueating to decreased renal clearance.

Additive Pharmacodynamic Effects: The risk of serious bleeding complications is officially increased when used concurrently with anticoagulants, antiplatelet agents, SSRIs, and Pentoxifylline. The natriuretic effect of Diuretics and the antihypertensive effect of ACE Inhibitors/ARBs may be officially diminished.

Other Constraints: The parenteral formulation must not be mixed in a small volume (e.g., in a syringe) with morphine sulfate, promethazine hydrochloride, or hydroxyzine hydrochloride due to physical incompatibility and risk of precipitation. Alcohol consumption is stated to increase the risk of gastrointestinal irritation and bleeding. The oral form's absorption rate ( T max) is officially delayed by a high-fat meal.

Mechanism of Action

How Pair Works: Pharmacodynamic Mechanism

Pair functions as a selective, competitive inhibitor that targets the farnesyl pyrophosphate synthase (FPPS) enzyme. This enzyme is an integral component of the mevalonate pathway, responsible for the conversion of geranyl pyrophosphate (GPP) into farnesyl pyrophosphate (FPP).

Pair’s molecular structure allows it to bind tightly and stably to the active site of FPPS. This high-affinity interaction effectively blocks the enzyme's catalytic function, resulting in a significant decrease in intracellular FPP production. This action serves to slow the overall flux through the distal segment of the mevalonate pathway.

The resulting reduction in FPP availability directly suppresses the post-translational prenylation of various cellular signaling proteins, most notably small GTPases such as Ras and Rho. As prenylation is a requisite step for these proteins to properly anchor to the cell membrane, their inability to localize functionally inhibits their signal transduction activity. This cascade disrupts crucial intracellular processes, representing the core physiological modulation exerted by Pair.

Dosage and Administration Information

How to Use Pair: Administration Guidelines

Pair is administered orally, following a fixed schedule to ensure consistent therapeutic delivery. This section outlines the procedural steps and rules for use.

Administration Details

Feature Administration Rule
Route Oral
Dosing One (1) tablet (20 mg) once daily.
Timing May be taken with or without food.
Preparation Swallow the tablet whole. No dilution, crushing, or breaking is permitted.
Age Group Use in adults (18 years and older) only.

Procedural Instructions

  • Daily Dose: Take one 20 mg tablet of Pair at approximately the same time each day.
  • Missed Dose: If a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is skipped and the regular dosing schedule is resumed. Two doses should not be taken to make up for a missed dose.
  • Consistency: Adherence to the once-daily schedule is utilized for maintaining the intended effect.

Procedural Context

These guidelines define the method for administering Pair. These instructions are procedural and do not address safety information, therapeutic uses, or potential benefits.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pair

This overview describes the types of research that have been conducted on Pair (Ketorolac tromethamine), focusing on the conditions studied, the outcomes measured, and where scientific evidence remains limited or uncertain.


Evidence for Short-Term Postoperative Pain Management

Studies monitored outcomes related to symptom change and primarily used short-term Randomized Controlled Trials (RCTs) in adult populations. These trials were designed to examine the drug's role in managing outcomes related to physical discomfort following various surgeries. Researchers evaluated episodes where symptom intensity or variability was heightened immediately after surgery.

Findings describe patterns observed in the studies related to changes in short-term pain intensity. Numerous trials reported patterns in co-consumption of opioid analgesics when Pair was observed alongside other pain management strategies. This evidence contributes to understanding symptom patterns during the immediate recovery phase, but the follow-up durations were limited to the mandated treatment time, generally not exceeding five days. Therefore, long-term symptom patterns are not fully established.


Evidence for Ophthalmic (Eye) Uses

Research has also explored the topical ophthalmic solution for use in conditions linked to inflammatory or irritative states in the eye, such as pain and inflammation following specific procedures like cataract surgery. The evidence structure is based on vehicle-controlled RCTs, where the medication was compared to an inactive solution.

Studies monitored outcomes related to inflammatory markers and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies where the use of the eye drops was associated with differences in both measured inflammation and reported discomfort compared to the inactive vehicle. This evidence is specific to topical application and does not provide insight into systemic use.


Research in Specific Patient Groups and Gaps

Evidence was primarily evaluated in adults. Research on pediatric populations (children and adolescents) for postoperative pain exists, but the evidence quality varies across studies, and findings were mixed or less consistent. Information for older adults with multiple health conditions is often derived from smaller trial subgroups, meaning subgroup findings are uncertain.

One of the most notable limitations across almost all systemic studies is that the follow-up durations were limited. This means research exploring short-term symptom changes does not provide comprehensive insight into long-term effects or outcomes beyond the five-day limit. Additionally, comparative evidence is lacking regarding its patterns versus all other possible analgesic strategies.

Frequently Asked Questions (FAQ)

Common questions about Pair (FAQ)

Q: How quickly does Pair start working after you take it?

Official regulatory information indicates that the pain-relieving effect of Pair generally begins within 30 minutes after a dose. The maximum pain-relieving effect is often reported to occur around two to three hours after administration.


Q: How long do the effects of a dose of Pair last?

According to the official product information, the pain-relieving effects of a single dose of Pair are usually maintained for approximately four to six hours. This duration aligns with its intended use as a short-term treatment for acute pain.


Q: Can Pair be taken with natural supplements?

Regulatory documents provide detailed information about known interactions with many prescription and over-the-counter medications. However, official labels do not typically detail specific interactions with every herbal or natural supplement. Disclosing all supplements used to a healthcare provider is generally recommended to evaluate potential risks.


Q: Can Pair be taken while breastfeeding?

Official regulatory information states that the use of Pair is contraindicated, or officially prohibited, for nursing mothers. The active ingredient in Pair is known to be excreted into human breast milk, and therefore, its use must be avoided during lactation.


Q: Is there a generic version of Pair available?

Yes, Pair is the brand name for the active ingredient Ketorolac tromethamine. This medication is widely available from various manufacturers in its generic form. Information regarding specific generic products is generally available via official regulatory databases.


Q: Can Pair be taken at the same time as other chronic medications?

Regulatory guidelines list several groups of chronic medications, such as lithium, methotrexate, and blood thinners, that have known interactions with Pair. Taking them together may increase the risk of side effects or change the medications' effectiveness. Any considerations regarding the timing of administration alongside chronic medications are best addressed by a prescriber.


Q: What's the main difference between Pair and similar treatments like [Competitor Drug Name]?

Pair is classified as a potent Nonsteroidal Anti-Inflammatory Drug (NSAID) indicated for the short-term management of moderately severe acute pain, such as pain after surgery. Unlike common NSAIDs, its use is strictly limited to a maximum of five days. This is primarily due to its classification and the safety constraints related to prolonged use.


Q: Is Pair safe for older adults or the elderly?

Regulatory labels state that older adults, generally those 65 years and older, are at a greater risk for developing serious side effects, particularly those affecting the stomach and kidneys. Regulatory guidance indicates that patients in this age group may require a reduced maximum daily limit and careful management.


Q: Does taking Pair require any specific blood tests or monitoring?

Official regulatory warnings emphasize the need for careful clinical monitoring. This monitoring is focused on watching for signs and symptoms of serious adverse effects, such as gastrointestinal bleeding and kidney problems, especially in patients with pre-existing risks or those on certain interacting medications.


Q: Why do doctors often prescribe Pair for [Condition Name]?

Pair is a non-narcotic analgesic indicated for moderately severe acute pain. It is often prescribed because it can provide strong pain relief at the level of some opioids without the central nervous system effects or dependence risks associated with narcotics.


Q: What should I do if the side effects of Pair feel bothersome?

Official patient information suggests that patients may consider seeking medical advice for bothersome side effects that persist. Serious adverse events, such as those involving the stomach or breathing, should be addressed as a medical emergency.


Q: What is the mechanism of action for Pair?

Pair is an NSAID. Its mechanism of action involves stopping the body’s production of chemical messengers called prostaglandins. Since prostaglandins are key factors in generating pain signals and causing inflammation, inhibiting their production helps to relieve both pain and swelling.


Q: Is Pair addictive or habit-forming?

No. Official regulatory information confirms that Pair is a non-narcotic medication and is not regulated as a controlled substance. It does not carry the same risks of dependence or habit-forming potential associated with opioid pain relievers.


Q: Are there different strengths or formulations of Pair available?

Yes, Pair is available in different forms for different uses, including an oral tablet and solutions for injection. The oral tablet is typically available in one strength, while the injectable solutions may be available in multiple concentrations.


Q: How long does it take to see the full benefits of Pair?

Pair is officially indicated only for the short-term management of acute pain, with a mandated maximum treatment duration of five days. The full therapeutic effect is expected to be achieved during this short course for the relief of the specific acute pain episode.


Q: Is Pair the same type of medication as [Another Drug Class/Type]?

The active ingredient in Pair, Ketorolac tromethamine, is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification helps distinguish it pharmacologically from other major pain-relieving classes.


Q: Are there common reasons why a doctor might switch someone from Pair to a different drug?

The primary reason for switching is the mandatory five-day limit on its use. Due to the risk of serious side effects with longer use, official instructions require that the medication be discontinued after five days, necessitating a transition to an alternative analgesic for ongoing pain management.


Q: How does Pair compare in effectiveness to older treatments for the same condition?

Official regulatory descriptions classify Pair as providing pain relief at the opioid-analgesic level of efficacy. This classification indicates its strong effect and distinguishes its intended use from many standard, over-the-counter pain treatments.


Q: What happens when you stop taking Pair?

Since Pair is a non-narcotic medication, there are no official regulatory warnings regarding withdrawal symptoms or physical dependence when the medication is stopped after its prescribed short-term use. It is simply discontinued once the acute pain is managed or the five-day limit is reached.

How should Pair be stored and disposed of?

Storage and Disposal Instructions

The medicine PAIR (Ketorolac tromethamine) must be stored strictly according to regulatory specifications to maintain its stability.

Storage Conditions

PAIR must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from light and moisture, and therefore should not be stored in a bathroom. Keep the medicine in its original container, which must be tightly closed. Liquid forms (injectable and ophthalmic) must be kept from freezing or refrigeration. All forms must be stored out of the sight and reach of children and pets.

Stability and Disposal

The ophthalmic solution must be discarded one month after the bottle is opened. Unused or expired PAIR should be disposed of via a drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance, seal the mixture in a container, and discard it with the household trash. Do not flush PAIR down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pair found in:

A-Z Index: